Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

A Phase 1 Study of THR 687, an RGD Integrin Antagonist, for the Treatment of Diabetic Macular Edema (DME) in Patients Previously Responsive to anti VEGF Agents or Corticosteroids*

*A prospective, Phase 1 (NCT03666923), dose escalation study to evaluate the safety of a single intravitreal (IVT) injection of THR-687 in previously treated subjects with center-involved DME (CI-DME)

Raj K. Maturi, MD

Victor H. Gonzalez, S. Jin Moon, Sunil S. Patel, Pravin U. Dugel, Petra Kozma, Arshad M. Khanani

Publication date: 
September, 2021